ESCARCEGA R O, FUENTES-ALECANDRO S, GATICA A, et al. The transcription factor nuclear factor-kappa B and cancer[J]. Clinical Oncology, 2007, 19(2):154-161.
[2]
KERR J F, WYLLIE A H, CURRIE A R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics[J]. British of Journal of Cancer, 1972, 26:239-257.
[3]
DOI T S, MATINO M W, TAKAHASHI T, et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality[J]. Proceeding of the National Academy Sciences of the United States of America, 1999, 96(6):2994-2999.
[4]
VERMEULEN L, VANDEN B W, HAEGEMAN G. Regulation of NF-kappaB transcriptional activity[J]. Cancer Treatment and Research, 2006, 130:89-102.
[5]
MALEWICZ M, ZELLER N, YILMAZ Z B, et al. NF-κB controls the balance between Fas and tumor necrosis factor cell death pathways during T cell receptor-induced apoptosis via the expression of its target gene A20[J]. The Journal of Biological Chemistry, 2003, 278:32825-32833.
[6]
ZAZZERONI F, PAPA S, ALVAREZ K, et al. Gadd45β mediates the protective effects of CD40 costimulation against Fas-induced apoptosis[J]. Blood, 2003, 102(9):3270-3279.
[7]
BAICHWAL R, BAEUERLE A. Apoptosis: activate NF-κB or die?[J]. Current Biology, 1997, 7(2):94-96.
[8]
DUMONT A, HEHNER S P, HOFMANN T G, et al. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kappa B[J]. Oncogene, 1999, 18(3): 47-757.
[9]
IVANOV V, RONAI Z. P38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappa B activity and Fas expression[J]. Oncogene， 2000, 19:3003-3012.
[10]
CHEN X, KANDASAMY K, STIVASTAVA R K. Differential roles of RelA(65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling[J]. Cancer Research, 2003, 63:1059-1066.
[11]
OUALI A, HERRERA-MENDEZ C H, COULIS G, et al. Revisiting the conversion of muscle into meat and the underlying mechanisms[J]. Meat Science, 2006, 74(1):44-58.
[12]
COMMUNAL C, SUMANDEA M, TOMBE P, et al. Functional consequences of caspase activation in cardiac myocytes[J]. Proceedings of the National Academy of Sciences of the United States of America,2002, 99(9):6252-6256.
GHOSH S, MAY M J, KOPP E B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses[J]. Annual Review Immunology, 1998, 16:225-260.
[22]
HUXFORD T, MALRK S, GHOSH G. Structure and mechanism in NF-kappa B/I kappa B signaling[J]. Cold Spring Harbor Symposia on Quantitative Biology, 1999, 64:533-540.
[23]
PEREIRA S G, OAKLEV F. Nuclear factor-kappa B1: regulation and function[J]. The International Journal of Biochemistry and Cell Biology, 2008, 40(8):1425-1430.
[24]
MALEK S, HUANG D B, HUXFORD T, et al. X-ray crystal structure of an I kappa Beta ×NF-kappa B p65 homodimer complex[J]. The Journal of Biological Chemistry, 2003, 278:23094-23100.
[25]
UEDA M, KOKURA S, IMAMOTO E, et al. Blocking of NF-κB activation enhances the tumor necrosis factor α-induced apoptosis of a human gastric cancer cell line[J]. Cancer Letters, 2003, 193(2):177-182.
[26]
BONIZZI G, KARIN M. The two NF-kappa B activation pathway and their role in innate and adaptive immunity[J]. Trends in Immunology, 2004, 25(6):280-288.
[27]
LUO J L, KAMATA H, KARIN M. IKK/NF-kappa B signaling: balancing life and death-a new approach to cancer therapy[J]. The Journal of Clinical Investigation, 2005, 115:2625-2632.
[28]
KARIN M, BEN-NEFINH Y. Phosphorylation meets ubiquitination: the control of NF-κB activity[J]. Annual Review of Immunology, 2000, 18:62l-663.
[29]
SENFTLEBEN U, CAO Y, XIAO G, et al. Activation by IKK alpha of a second, evolutionary conserved, NF-kappa B signaling pathway[J]. Science, 2001, 293(5534):1495-1499.
[30]
CAMPBELL K J, ROCHA S, PERKINS N D. Active repression of antiapoptotic gene expression by RelA(65)NF-kappa B[J]. Molecular Cell, 2004, 13(6):853-865.
